Focused on blockbuster indications, Sage touts evidence that 217 could work on insomnia
After whipping up some giddy blockbuster expectations for their oral drug SAGE-217 in depression, Sage Therapeutics is back this morning with an early snapshot on new data for another mass market — insomnia.
Touting the drug’s ability to “rebalance fundamental brain circuitry,” researchers spotlighted a Phase I/II hit for several measures on improving the amount of sleep insomniacs can achieve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.